American Journal of Clinical Dermatology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Relationship of Histopathologic Parameters and Gene Expression Profiling in Malignant Melanoma
ConclusionsAn association, but no definitive prediction, exists between histopathologic categories of depth of invasion, melanoma subtype, and presence or absence of ulcer and gene expression profiles. GEP adds valuable data to the evaluation of malignant melanomas that cannot be definitively predicted by conventional models. The findings add to needed groundwork for comparison of traditional markers and molecular genotyping and begins to build a robust predictive model for better outcomes in patients with malignant melanoma. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - September 4, 2023 Category: Dermatology Source Type: research

Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study
ConclusionsApremilast treatment demonstrated greater improvements in disease severity and patient-reported symptoms versus placebo at week 16 in Japanese patients with PPP with sustained improvements through week 32. No new safety signals were observed.ClinicalTrials.govNCT04057937. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - September 1, 2023 Category: Dermatology Source Type: research

Atopic Dermatitis Across Shades of Skin
AbstractAtopic dermatitis (AD) is a chronic, heterogeneous inflammatory skin disease that is associated with immense patient burden globally. There is increasing appreciation of disparities among patients identified as having skin of color (SOC), which often refers to patients of non-White race or non-European ancestry, but can broadly include individuals from a number of different racial, ethnic, ancestral, and skin pigmentation groups based on definition. In this narrative review, we discuss key terminology as it relates to AD across shades of skin, including modern definitions of ‘race’, ‘ethnicity’, and ‘SOC�...
Source: American Journal of Clinical Dermatology - September 1, 2023 Category: Dermatology Source Type: research

Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials
ConclusionsSecukinumab was well tolerated in pediatric patients with moderate to severe and severe plaque psoriasis across age and bodyweight subgroups. The overall safety profile of secukinumab in pediatric patients was consistent with that of adult patients.ClinicalTrials.gov IdentifierNCT03668613 (Novartis Study Code CAIN457A2311, referred to as A2311), actual study start date: August 29, 2018; actual primary completion date: September 19, 2019; estimated study completion date: September 14, 2023. NCT02471144 (Novartis Study Code CAIN457A2310, referred to as A2310), study start date: September 29, 2015; primary completi...
Source: American Journal of Clinical Dermatology - September 1, 2023 Category: Dermatology Source Type: research

Association Between the Use of Topical Calcineurin Inhibitors and the Risk of Cancer Among Patients with Atopic Dermatitis: A Nationwide, Population-Based, Retrospective Cohort Study
Conclusions and RelevanceOur study found no evidence to support an association between TCI use and the risks of almost all cancers compared with TCS use in patients with AD, but physicians should be aware of potentially higher risks of leukemia with TCI use. This study represents the first population-based study focused on the cancer risk of TCI use among patients with AD in an Asian population. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - September 1, 2023 Category: Dermatology Source Type: research

Dupilumab Provides Clinically Meaningful Responses in Children Aged 6 –11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial
ConclusionTreatment with dupilumab provides significant and sustained improvements within 2 weeks in AD signs, symptoms, and QoL in almost all children with severe AD, including those who did not achieve clear or almost clear skin by week 16.Trial RegistrationNCT03345914.Video Abstract: Does dupilumab provide clinically meaningful responses in children 6 to 11 years old with severe atopic dermatitis? (MP4 99484 kb) (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - September 1, 2023 Category: Dermatology Source Type: research

Capturing the Diversity of Dermatology —What’s in a Name?
AbstractAs research related to skin of color (SOC) in dermatology continues to grow, it is increasingly important to precisely define terminology. The terms ‘SOC’, ‘race’, and ‘ethnicity’ are frequently used to analyze differences in dermatologic disease onset, severity, and outcomes. These terms are used interchangeably, are ill-defined across research studies, and frequently conflate biologic and socially constructed categories. SOC has be en thought to represent differing degrees of pigment or melanin in the skin, however skin pigment is quite variable among races and ethnicities. Furthermore, certain indivi...
Source: American Journal of Clinical Dermatology - September 1, 2023 Category: Dermatology Source Type: research

Targeting Inflammation in Acne: Current Treatments and Future Prospects
This article will provide an overview of emerging treatments of acne and their link to our current and improved understanding of acne pathogenesis. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - September 1, 2023 Category: Dermatology Source Type: research

Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
This article reviews the current evidence about lebrikizumab in the management of AD. The phase II and phase III trials seem to corroborate efficacy of lebrikizumab in the treatment of moderate-to-severe AD, as shown by significant improvement of Eczema Area and Severity Index, body surface area, and pruritus scores. Also, lebrikizumab demonstrated favorable safety and tolerability profiles, with the majority of patients experiencing no significant adverse events. Lebrikizumab seems to be a promising emerging targeted biological agent for patients with moderate-to-severe AD. More data on the long-term efficacy and safety, ...
Source: American Journal of Clinical Dermatology - September 1, 2023 Category: Dermatology Source Type: research

Efficacy and Safety of Nail Psoriasis Targeted Therapies: A Systematic Review
ConclusionNumerous targeted therapies have shown significant efficacy in improving nail findings in patients with psoriasis and psoriatic arthritis. Data from head-to-head trials have shown greater efficacy of ixekizumab over adalimumab and ustekinumab, as well as brodalumab over ustekinumab, while prior meta-analyses have demonstrated superiority of ixekizumab and tofacitinib to other included agents at various assessed timepoints. Further studies on the long-term efficacy and safety of these agents, as well as randomized controlled trials involving comparison with placebo arms, are needed to fully analyze differences in ...
Source: American Journal of Clinical Dermatology - September 1, 2023 Category: Dermatology Source Type: research

Diagnosis and Management of Dermatologic Adverse Events from Systemic Melanoma Therapies
AbstractThe advent of protein kinase inhibitors and immunotherapy has profoundly improved the management of advanced melanoma. However, with these therapeutic advancements also come drug-related toxicities that have the potential to affect various organ systems. We review dermatologic adverse events from targeted (including BRAF and MEK inhibitor-related) and less commonly used melanoma treatments, with a focus on diagnosis and management. As immunotherapy-related toxicities have been extensively reviewed, herein, we discuss injectable talimogene laherparepvec and touch on recent breakthroughs in the immunotherapy space. D...
Source: American Journal of Clinical Dermatology - September 1, 2023 Category: Dermatology Source Type: research

Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Beh çet’s Syndrome
ConclusionsThe incidence of serious TEAEs and TEAEs of special interest was low despite long-term exposure, further establishing apremilast as a safe oral option for long-term use across indications with a favorable benefit –risk profile.Clinical Trial RegistrationNCT00773734, NCT01194219, NCT01232283, NCT01690299, NCT01988103, NCT02425826, NCT03123471, NCT03721172, NCT01172938, NCT01212757, NCT01212770, NCT01307423, NCT01925768, NCT00866359, NCT02307513.Graphical Abstract (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - September 1, 2023 Category: Dermatology Source Type: research

Authors ’ Reply to Chen and Chen: Comment on: “Isotretinoin Exposure and Risk of Inflammatory Bowel Disease: A Systematic Review with Meta-Analysis and Trial Sequential Analysis”
(Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - September 1, 2023 Category: Dermatology Source Type: research